year 18, Issue 71 (9-2019)                   J. Med. Plants 2019, 18(71): 1-5 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Zamani Z, Akhondzadeh S. Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review. J. Med. Plants 2019; 18 (71) :1-5
1- Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
2- Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran ,
Abstract:   (3254 Views)
Obsessive compulsive disorder (OCD) is a severe and debilitating neuropsychiatric condition that is characterized by recurrent and intrusive thought that the affected individual feels compelled to perform in order to reduce the distress. It affects between 1 to 3% of the general population around the world and has some gender-related features. Although selective serotonin reuptake inhibitors, tricyclic antidepressants and cognitive-behavioral therapy are the first line medication and treatment of OCD, an estimated 30% of patients are treatment-resistant and complete functional recovery is rare. Therefore, several researches and trials have been done to develop new pharmacotherapeutic agents or modulate different neurotransmitters for treatment of OCD. In this concept alternative medicine and particular herbal medicine are very interesting in this issue. We focus on some herbal medicine in the treatment of OCD in this review.
Full-Text [PDF 295 kb]   (3622 Downloads)    
Type of Study: Review | Subject: Medicinal Plants
Received: 2018/09/23 | Accepted: 2019/01/17 | Published: 2019/08/24

1. Get persistent links for your reference list or bibliography. Copy and paste the list, we’ll match with our metadata and return the links. Members may also deposit reference lists here too. 1. Abramowitz JS, Taylor S and McKay D. Obsessive-compulsive disorder. Lancet 2009; 374: 491-9. [DOI:10.1016/S0140-6736(09)60240-3]
2. Ruscio AM, Stein DJ, Chiu WT and Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Molecular Psychiatry 2010; 15: 53-63. [DOI:10.1038/mp.2008.94] [PMID] [PMCID]
3. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 2012; 15: 1173-91. [DOI:10.1017/S1461145711001829] [PMID]
4. Pittenger C, Krystal JH and Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006; 3: 69-81. [DOI:10.1016/j.nurx.2005.12.006] [PMID] [PMCID]
5. Graybiel AM and Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. Neuron 2000; 28: 343-7. [DOI:10.1016/S0896-6273(00)00113-6]
6. Nsel TR, Mueller EA, Alterman I, Linnoila M and Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biological Psychiatry 1985; 20: 1174-88. [DOI:10.1016/0006-3223(85)90176-3]
7. Ghaleiha A, Asadabadi M, Mohammadi MR, Shahei M, Tabrizi M, Hajiaghaee R, Hassanzadeh E and Akhondzadeh S. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. International Journal of Neuropsychopharmacol. 2013 May; 16 (4): 783-9. [DOI:10.1017/S1461145712000880] [PMID]
8. Asadabadi M, Mohammadi MR, Ghanizadeh A, Modabbernia A, Ashrafi M, Hassanzadeh E, Forghani S and Akhondzadeh S. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013; 225 (1): 51-9. [DOI:10.1007/s00213-012-2796-8] [PMID]
9. Khodaie-Ardakani MR, Mirshafiee O, Farokhnia M, Tajdini M, Hosseini SM, Modabbernia A, Rezaei F, Salehi B, Yekehtaz H, Ashrafi M, Tabrizi M and Akhondzadeh S. Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. Psychiatry Research 2014; 215 (3): 540-6. [DOI:10.1016/j.psychres.2013.12.051] [PMID]
10. Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z and Akhondzadeh S. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Hum. Psychopharmacol. 2017 Jul; 32 (4). [DOI:10.1002/hup.2584] [PMID]
11. Esalatmanesh S, Abrishami Z, Zeinoddini A, Rahiminejad F, Sadeghi M, Najarzadegan MR, Shalbafan MR and Akhondzadeh S. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial. Psychiatry and Clinical Neuroscience 2016; 70 (11): 517-526. [DOI:10.1111/pcn.12430] [PMID]
12. Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J and Akhondzadeh S. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. International Clinical Psychopharmacol. 2014; 29 (6): 344-50. [DOI:10.1097/YIC.0000000000000043] [PMID]
13. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R and Akhondzadeh S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J. Psychiatric Res. 2013; 47 (2): 175-80. [DOI:10.1016/j.jpsychires.2012.09.015] [PMID]
14. Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R and Akhondzadeh S. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2012; 26 (10): 883-92. [DOI:10.2165/11635850-000000000-00000] [PMID]
15. Sarris J, Camfield D and Berk M. Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review. Journal of Affective Disorders 2012; 138 (3): 213-21. [DOI:10.1016/j.jad.2011.04.051] [PMID]
16. Sayyah M, Boostani H, Pakseresht S and Malayeri A. Comparison of Silybum marianum (L.) Gaertn. with fluoxetine in the treatment of Obsessive-Compulsive Disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 2010; 34 (2): 362-5. [DOI:10.1016/j.pnpbp.2009.12.016] [PMID]
17. Esalatmanesh S, Biuseh M, Noorbala AA, Mostafavi SA, Rezaei F, Mesgarpour B, Mohammadinejad P and Akhondzadeh S. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial. Iranian Journal of Psychiatry 2017; 12 (3): 154-162.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Medicinal Plants

Designed & Developed by : Yektaweb